CARDIOTOXICITY CAUSED BY INTRAVESICAL DOXORUBICIN (DOX) AFTER TURBT: A CASE REPORT

Abstract

Abstract Introduction: Transurethral resection of bladder tumors (TURBT) remains the gold standard therapy for diagnosing and treating Non-Muscle Invasive Bladder Cancer (NMIBC). Post-operative intravesical chemotherapy with doxorubicin (DOX) is recommended to reduce recurrence. However, its cardiotoxic effects are underappreciated. The purpose of this case report is to raise awareness of the cardiotoxic effects of DOX during the treatment of bladder cancer.